ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
18 hedge funds and large institutions have $10.4M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
5.73% more ownership
Funds ownership: 27.51% → 33.25% (+5.7%)
8% less capital invested
Capital invested by funds: $11.3M → $10.4M (-$873K)
22% less funds holding
Funds holding: 23 → 18 (-5)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$2.25M |
| 2 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$59.7K |
| 3 |
RFWA
RPg Family Wealth Advisory
Burlington,
Massachusetts
|
+$26.9K |
| 4 |
LPL Financial
San Diego,
California
|
+$14.8K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$11.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$701K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$263K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$123K |
| 4 |
Citigroup
New York
|
-$49.6K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$39.6K |
CNCR Hedge Fund Activity: Q1 2020 in Review
18 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q1 2020, worth a combined $10.4M — down 7.7% from $11.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CNCR and 2 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was BCWM LLC, adding an estimated $2.25M. The largest seller was Morgan Stanley, cutting an estimated $701K.
- 18 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q1 2020, down from 23 in Q4 2019.
- Funds reported $10.4M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q1 2020, down 7.7% quarter-over-quarter.
- 2 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q1 2020 and 5 closed out, a net change of -3 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q1 2020 was BCWM LLC, an estimated $2.25M added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q1 2020 was Morgan Stanley, an estimated $701K sold.
Based on aggregated 13F filings for Q1 2020.